BioStem Technologies (OTC: BSEM), a regenerative medicine company specializing in perinatal tissue allograft products, announced the appointment of Katherine Gorrell as Chief Legal & Compliance Officer, effective April 27, 2026. Gorrell brings two decades of experience advising healthcare organizations on regulatory, governance, and growth initiatives.
In her new role, Gorrell will oversee BioStem's legal and compliance functions and play a central role in enterprise governance, including the integration and oversight of Medical Affairs through the company's compliance framework. This appointment comes as BioStem implements its next phase of growth, with an eye toward a Nasdaq uplisting.
"Katherine is a key addition to BioStem as we implement our next phase of growth," said Jason Matuszewski, Chairman and CEO of BioStem Technologies. "Katherine brings a demonstrated ability to partner effectively with boards and executive teams, and her leadership will support our continued scaling while reinforcing our strong foundation of integrity and compliance, especially as we progress toward a Nasdaq uplisting."
Most recently, Gorrell served as Vice President and General Counsel at Holy Cross Health in Fort Lauderdale, FL, where she was a member of the Executive Team and led legal strategy across a complex healthcare enterprise. She previously served as General Counsel and Compliance Officer for AdvancedMD, a national healthcare IT company, and held in-house roles at Intermountain Healthcare and Providence Health & Services/Swedish Health Services. Gorrell holds a JD with Honors, with a concentration in Health Law, from the University of Washington School of Law, and a Bachelor of Arts with Honors in Political Science from the University of Utah.
"BioStem is at a pivotal time in its growth and evolution," Gorrell said. "I look forward to working with the leadership team and board to support sustainable growth, strengthen governance, and ensure our legal, compliance, and medical affairs functions continue to evolve with the business."
BioStem Technologies develops and commercializes advanced allograft solutions derived from perinatal tissue, leveraging proprietary processing technologies such as BioRetain, CryoTek, and SteriTek. The company's quality management system is accredited by the American Association of Tissue Banks and complies with current Good Tissue Practices and current Good Manufacturing Processes. Its product portfolio includes Neox, Clarix, VENDAJE, and American Amnion.
The appointment signals BioStem's commitment to strengthening its leadership team as it scales operations and pursues a Nasdaq uplisting. The latest news and updates relating to $BSEM are available in the company's newsroom at https://tinyurl.com/bsemnewsroom.
